The emergence of new therapies to limit myopia progression offers eyecare practitioners (ECPs) the opportunity to deliver better health outcomes for their patients. Despite growing calls for myopia control to become the new standard of care,(1)uptake of these new treatments by practitioners is still limited....
Scientific and industrial innovators have responded to the threat posed by myopia. We now have a rapidly increasing range of treatments available which have been shown to delay myopia onset, reduce or eliminate the progression of myopia in some children and thereby reduce the risk...
According to a recent meta-analysis of published studies, approximately 11% of COVID-19 patients have exhibited direct ocular effects (1). Typically, the complications appear to be relatively mild and short-term. ...
The emergence of the COVID-19 pandemic has had an immediate and dramatic impact on eye care. Even now, more than a year since the emergence of this public health crisis, Covid-19 continues to overwhelm healthcare systems and resources around the globe. T...
We will now examine how a successful public health strategy for myopia might be implemented, and what policy measures might generate sufficient impact to reverse the myopia epidemic....
The management of myopia is typically practitioner-led. Currently, the standard of care is to provide single-vision spectacle or contact lenses to eliminate the blurred vision symptoms, which are characteristic of myopia. ...
In 20 years, will optometry as we know it exist? Will there be a role for optometry, and how will it be delivered?...
The global prevalence of myopia has reached unprecedented levels and current projections indicate that about half of the world’s population, 5 billion people, will be myopic by 2050. ...
Over two millennia ago, Aristotle (350BC) first coined the term myopia. He was likely describing the “closed eye” appearance of those squinting as a means to overcome their characteristically impaired distance vision...
